K. Amiri

发表

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

A. Gajra, H. Ali, D. Spigel, 2018, Frontiers in Oncology.

Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1

M. Smulson, A. Richmond, K. Amiri, 2006, Oncogene.

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways

J. Schmid, A. Richmond, Jinming Yang, 2006, Clinical Cancer Research.

Role of nuclear factor-kappa B in melanoma.

A. Richmond, K. Amiri, 2005, Cancer metastasis reviews.

BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways.

J. Schmid, A. Richmond, Jinming Yang, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

Fine tuning the transcriptional regulation of the CXCL1 chemokine.

A. Richmond, K. Amiri, 2003, Progress in nucleic acid research and molecular biology.

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group

J. Berlin, A. Benson, M. Mulcahy, 2014, Investigational New Drugs.

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence

R. Splittgerber, Yan Liu, J. Sosman, 2012, EMBO molecular medicine.

A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets

J. Sosman, G. Ayers, I. Puzanov, 2009, Clinical Cancer Research.

Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors

S. Levy, J. Sosman, R. Splittgerber, 2012 .

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

S. Levy, J. Sosman, R. Splittgerber, 2012, Clinical Cancer Research.

Role of nuclear factor-κ B in melanoma

A. Richmond, K. Amiri, 2005, Cancer and Metastasis Reviews.

Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition

Ann Richmond, Jeffrey A. Sosman, B. LaFleur, 2004, Cancer Research.

Constitutive activation of NF-kappaB in Melanoma offers a potential target for therapy.

A. Richmond, L. Horton, K. Amiri, 2004 .

Hairpin DNA coated gold nanoparticles as intracellular mRNA probes for the detection of tyrosinase gene expression in melanoma cells.

D. Wright, D. Hicks, K. Amiri, 2010, Chemical communications.

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

J. Weiss, A. Kalsekar, K. Amiri, 2022, JTO clinical and research reports.

ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).

Edward S. Kim, C. Langer, J. Goldman, 2017 .

Safety and efficacy of nab-paclitaxel (nab-P)–based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2.

A. Gajra, H. Ali, D. Spigel, 2017 .

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

M. Socinski, A. Gajra, H. Ali, 2016 .